Form 4: Dianthus Therapeutics Executive Adam Veness Reports Stock Option Grant

Adam Veness, SVP, General Counsel and Secretary of Dianthus Therapeutics, reports the acquisition of stock options.

Summary

• On May 23, 2024, Adam Veness, SVP, General Counsel and Secretary of Dianthus Therapeutics, Inc., was granted stock options to purchase 75,000 shares of common stock.
• The exercise price of the options is $21.77 per share.
• The options vest in equal monthly installments over four years, starting May 1, 2024, contingent upon continued service to the Issuer.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices. The grant of options suggests confidence in the company's future prospects.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing long-term value creation.

Risks

• The value of the stock options is dependent on the future performance of Dianthus Therapeutics' stock price.

Future Outlook

The vesting schedule suggests a commitment to the company for the next four years from the reporting person.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes management to increase shareholder value.

Key Dates